Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel
- 6 November 2020
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 137 (13), 1832-1835
- https://doi.org/10.1182/blood.2020006245
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumJournal of Clinical Oncology, 2020
- Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaHaematologica, 2020
- CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-CelBlood, 2019
- Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) RegistryBlood, 2019
- Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)Blood, 2019
- Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapyAmerican Journal of Hematology, 2019
- Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2018
- Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) TherapyBlood, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017